Shawnte Mitchell, J.D., is the Chief Legal Officer and Corporate Secretary at Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies targeting the estrogen receptor pathway for women's cancers. In this role, she leads all legal, regulatory, compliance, and corporate governance functions, providing strategic counsel to the executive team and Board of Directors. Mitchell plays a critical role in supporting Olema's clinical development programs, including its lead candidate OP-1250, through IPO readiness, partnerships, and navigating complex biotech regulatory landscapes. Prior to joining Olema in 2021, Mitchell served as Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Reata Pharmaceuticals, where she guided the company through its 2016 IPO and eventual $7.3 billion acquisition by Biogen in 2023. Her earlier career includes Vice President and Associate General Counsel at Orexigen Therapeutics, legal leadership at Relypsa, Inc. (acquired by Galenica), and roles at law firms such as Cooley LLP and Heller Ehrman LLP, specializing in life sciences transactions. A graduate of the University of California, Hastings College of the Law (J.D.) and the University of California, Berkeley (B.A. in Political Science), Mitchell brings over 20 years of experience in the pharmaceutical and biotechnology sectors. Her achievements encompass structuring multibillion-dollar deals, implementing enterprise-wide compliance programs, and fostering innovation in high-stakes environments, earning her recognition as a trusted advisor in the industry.